Drug intelligence / Profile preview

P144 cream

Development stage: Unknown
Lead developer: Digna Biotech
Modality: Peptides, Small Molecules
Administration: Topical

Overview

P144 cream is a topical formulation of the peptide inhibitor known as P144. It is being developed for the treatment of skin fibrosis in patients with systemic sclerosis (scleroderma). The mechanism of action involves inhibition of transforming growth factor-beta 1 (TGF-β1), a key cytokine implicated in fibrotic processes. By blocking TGF-β1 signaling, P144 aims to reduce or prevent excessive collagen deposition and fibrosis in affected skin. Clinical trials have evaluated its use as a topical therapy for scleroderma-related skin fibrosis[1][2].

Brand names: digna p144 creamp144 digna creamp-144 digna creamp 144 digna cream
Other names: P144 topicalP-144 topicalP 144 topicalP144 creamP-144 creamP 144 cream

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on P144 cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P144 cream.

Explore the full profile